There are ongoing clinical trials in the first-line advanced melanoma setting of combining nivolumab-relatlimab with ipilimumab which demonstrated encouraging efficacy data in preliminary reports along with improvement of safety with addition of IL-6R inhibitor.23,24. Here, IL6R is linked to melanoma.